What US drug tariffs mean for Indian pharma

A new US tariff clock threatens the cheap generics India supplies to the world. Natco Pharma's scramble to diversify shows how the industry is bracing, and what is really at stake for patients.

Washington has decided that too many of America's medicines are made abroad, and it wants that to change. Over the past few months the Trump administration has begun using tariffs to push drug manufacturing back onto American soil. For India, which supplies a large share of the world's, and America's, cheap generic medicines, that is a direct challenge to one of its most successful export industries. The clearest way to understand the stakes is through a company like Natco Pharma, the Hyderabad-based specialist whose fortunes are tied to the United States, and whose recent moves read like a case study in how Indian pharma is preparing for what comes next.

What has Washington actually done?

In April 2026, the administration signed a proclamation under Section 232, a national-security trade law, imposing a 100 per cent tariff on imported patented drugs and their active ingredients, phased in from the middle of the year. Generic medicines, the low-cost copies that make up the overwhelming majority of prescriptions filled in America, were left out, for now. Then, in July 2026, the president set a clock ticking on generics too: a proposed tariff of zero until 2028, then 100 per cent, then 200 per cent from 2029, unless companies build manufacturing capacity in the United States. As of now that generics threat is still an announcement rather than a formal, detailed order, but the direction is unmistakable: make it in America, or pay.

Why does it matter for India?

India is the pharmacy of the world's generics, and the United States is its single biggest customer. Indian companies supply a large share, by volume, of the generic medicines Americans take every day, from cancer drugs to everyday tablets. For the big Indian drugmakers, the US market often accounts for a third or more of revenue. A tariff wall on generics would land squarely on that business. Natco is a sharp example. Its most profitable product in years has been gRevlimid, its US copy of the cancer drug Revlimid, and the American market is where its patent-challenge strategy pays off. A future tax on generic exports would strike at the very engine that has powered its best years.

Will it actually work?

Here is the catch, and it is the part most analysts keep returning to: reshoring the manufacture of ordinary generics to the United States may simply not be viable. These are high-volume, low-margin products, and the economics only work because they are made cheaply in places like India. American manufacturing costs are far higher, and the margins on a commodity pill are too thin to absorb them. The likelier outcome of steep tariffs, many experts warn, is not a wave of new US factories but higher prices, discontinued products and drug shortages, especially for the cheap injectables that already run out too often. Only complex, higher-value medicines might justify an American plant. And with the deadline falling in a US election year, plenty in the industry are betting the plan will be softened or negotiated away before it ever bites.

Where does Natco fit?

Natco's US business is entirely in generics, so it is exempt from today's tariff on patented drugs. But the 2028 threat points straight at its core: the patent-challenge business in America that has driven its most profitable years. The company's answer, tellingly, was set in motion well before the latest headlines: diversify, so that no single market or molecule decides its fate. Only a few years ago, Natco's earnings came almost entirely from the United States; today they come from five markets. It has bought its way to a 49 per cent stake in Adcock Ingram, South Africa's second-largest drugmaker, for about INR 1,060 crore, a deal that lifts the combined enterprise past USD 1 billion in revenue. It is building front-ends in Brazil and Canada, each already worth a few hundred crore a year, and it is leaning harder on its home market in India, where it recently launched a low-cost generic of the weight-loss drug semaglutide. With roughly INR 2,400 crore of net cash on hand, it is hunting for more acquisitions, and Rajeev Nannapaneni, its vice-chairman and chief executive, has been candid that he would rather spend that money abroad, where valuations look kinder, than at home.

"What we are doing deliberately now is building a diversified portfolio so that our earnings are more diversified," Nannapaneni has said, adding that he is "bullish outside India."

There is a second layer of protection, too. Natco does not make cheap, commodity pills so much as complex, hard-to-copy medicines, the kind that take years of research and patent litigation to bring to market. Those are precisely the higher-value products that might one day justify the cost of an American plant, and that are least likely to be squeezed out by a tariff aimed at low-margin generics. In a trade war over medicines, difficulty is a defence.

Rajeev Nannapaneni, vice-chairman and ceo, Natco Pharma

"I always believe that true success only comes if you're willing to play the game for the long haul. If you want great things to happen in the next 5 years, you have to invest for the long term, which means having the ability to ignore short-term earnings volatility. When you invest in something, you have to believe it will work, and that it will take time to build a global company."

And what about the patients?

Strip away the trade politics and a simpler question remains: who pays? Cheap Indian generics are the reason expensive medicines become affordable, and not only in India. Natco built its name on exactly this. It produced India's first generic of the cancer drug Nexavar under the country's first-ever compulsory licence in 2012, cutting the monthly cost by more than 95 per cent, from around INR 2.8 lakh to INR 8,800. Its imatinib brought chronic-leukaemia treatment down by more than 90 per cent; its risdiplam took a rare-disease therapy from INR 6.2 lakh a bottle to about INR 15,900 a month; and it recently launched a generic weight-loss vial in India at roughly INR 1,000 a month, against branded pens many times the price. That is the deeper irony of the tariff push. A policy meant to secure America's drug supply could end up making medicines costlier and scarcer for American patients, while the Indian model it targets has spent two decades doing the opposite: driving prices down and access up.

What to watch

For now, the patented-drug tariff is live and the generics clock is set for 2028, but the details, and whether it survives an election year, are far from settled. Expect Indian makers to keep hedging: spreading into new geographies, moving up into complex and specialty products, and, in a few cases, weighing small US investments. Natco's bet is that diversification and difficulty are the best insurance. As Nannapaneni likes to point out, in this business you have to play the long game. The tariff question has just made that lesson a great deal more urgent.